Lava is a biotechnology company that develops next-generation biospecific antibodies for cancer therapies.
Business Model:
Revenue: $4.3M
Employees: 11-50
Address: Yalelaan 60
City: Utrecht
State: utrecht
Zip: 3584 CM
Country: NL
Lava is a biotechnology company that develops next-generation biospecific antibodies for cancer therapies.
Contact Phone:
Contact Email:
Listed Exchange:
NASDAQ
IPO Date:
3/24/2021
IPO Valuation:
$380M
Ticker Symbol:
LVRX
IPO Price:
$15/share
Amount Raised:
$101M
Opened: -/share
EBITDA | - |
Total Cash | - |
Total Debt | - |
Total Revenue | - |
Total Profit (Gross) | - |
PE Ratio | - |
Announced Date | Company | Transaction | Money Raised |
---|
Announced Date | Transaction | Number of Investors | Money Raised | Lead Investors | 5/2018 | Equity | $18.9M |
Gilde Healthcare Versant Ventures MRL Ventures Fund Lupus Ventures |
5/2018 | Series A | 3 | $18.7M |
Kinled Holding Versant Ventures Gilde Healthcare Versant Ventures Kinled Holding Versant Ventures Gilde Healthcare Versant Ventures |
9/2020 | Series C | 8 | $83M |
Sanofi Ventures Versant Ventures Novo Ventures Gilde Healthcare Pureos Bioventures Ysios Capital Redmile Group MRL Ventures Fund Novo Ventures Sanofi Ventures Sanofi Ventures Versant Ventures Novo Ventures Gilde Healthcare Pureos Bioventures Ysios Capital Redmile Group MRL Ventures Fund Novo Ventures Sanofi Ventures |
6/2017 | Seed | $1.1M | 3/2021 | IPO | $100.5M |
|
6/2017 | Seed Round | $1.1M | 5/2018 | Series A | 3 | $18.7M |
Kinled Holding Versant Ventures Gilde Healthcare Versant Ventures Kinled Holding Versant Ventures Gilde Healthcare Versant Ventures |
6/2017 | Seed Round | $1.1M |
---|
Announced Date | Name | Price |
---|
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|